Sanofi, GSK Say Covid Vaccine Shows Positive Result

The vaccine "achieved strong rates of neutralizing antibody responses, in line with those measured in people who have recovered from COVID-19," the companies said in a statement

French pharmaceuticals giant Sanofi and Britain's GSK reported on Monday "strong immune responses" in early tests of their Covid-19 vaccine, raising hopes it could join the fight against the pandemic. The companies said the results of the Phase 2 study will enable them to move to a late-stage trial in the coming weeks -- a reversal of fortune after their research was dealt a setback late last year. The experimental vaccine "achieved strong rates of neutralizing antibody responses, in line with those measured in people who have recovered from COVID-19, in all adult age groups in a Phase 2 study with 722 volunteers," it said in a statement. "A global pivotal Phase 3 study is expected to start in the coming weeks."